Pfizer says FDA okays arthritis drug

Get the weekly rundown
Sign up to receive our weekly BizBuzz newsletter

Pfizer says the Food and Drug Administration approved its rheumatoid arthritis pill Xeljanz, seen as potential big seller for the company.

Pfizer Inc. says the FDA approved Xeljanz as a treatment for moderate to severe rheumatoid arthritis in patients who can't take methotrexate or haven't been helped by it. Xeljanz is intended to slow the progression of the disease. The approval comes about two weeks sooner than expected.

Xeljanz, or tofacitinib, is the first rheumatoid arthritis treatment from a new class of pain medications called JAK inhibitors. The drugs interfere with enzymes that contribute to tissue inflammation.

- Associated Press

READER COMMENTS

Loading comments...
Hide Comments

Stories that may interest you

Job Fair on Monday

Job Fair on Monday


Honda cutting production of Accords as buyers shift to SUVs

Honda is slowing production of Accord sedans as car buyers continue to favor SUVs and trucks


Worth the risk? It's not easy to put a value on a cathedral

Cultural monuments can be tough to value _ as the fire at Notre Dame has shown


Deregulation effort could slice rules for frozen cherry pies

President Donald Trump may soon be able to claim a sweet victory for his deregulation push: Officials are preparing to get rid of decades-old rules for frozen cherry pies

TRENDING

PODCASTS